Belite Bio shares jump on Canaccord Buy initiation for tinlarebant
Canaccord Genuity initiated Belite Bio with a Buy rating and $303 price forecast, citing upside tied to FDA-accepted tinlarebant marketing application. Shares were up 9.63% to $187.56.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.